Elranatamab

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Elranatamab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 2 molecular targets, including TNFRSF17 and CD3E. Recorded indications include Relapsed or refractory multiple myeloma.

• Molecular targets: TNFRSF17 and CD3E (2 listed in DrugCentral).
• Indications: Relapsed or refractory multiple myeloma.
• ATC code: L01FX32 (Other monoclonal antibodies and antibody drug conjugates).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Relapsed or refractory multiple myeloma

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Tumor necrosis factor receptor superfamily member 17	TNFRSF17	other	Kd 10.42
T-cell surface glycoprotein CD3 epsilon chain	CD3E	other	Kd 7.77

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-08-14	FDA	—	PFIZER INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01FX32	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cytokine release syndrome	1369.0
Immune effector cell-associated neurotoxicity syndrome	478.9
Cytomegalovirus infection reactivation	312.8
Cytomegalovirus infection	164.2
Hypogammaglobulinaemia	132.7
Malignant neoplasm progression	128.1
Death	97.2
Neoplasm progression	97.1
Neutropenia	75.6
Pyrexia	72.7
Second primary malignancy	64.4
Progressive multifocal leukoencephalopathy	63.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 2408850-14-4
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Elranatamab used for?

DrugCentral lists the following indications for Elranatamab: Relapsed or refractory multiple myeloma.

How does Elranatamab work?

Its molecular targets in DrugCentral include TNFRSF17 and CD3E.

When was Elranatamab first approved?

Elranatamab was first approved by the FDA in 2023.

Sources

• DrugCentral drug card 5741 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297809 — compound record and bioactivity
• DrugBank DB15395 — drug record
• FDA UNII L0HR9A577V — substance identity
• DailyMed: FDA labels for Elranatamab — current prescribing information (label search)
• UniProt Q02223 (TNFRSF17) — target protein
• UniProt P07766 (CD3E) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.